 Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands, octreotide or lanreotide. Results as of a February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine formerly CRN00808 maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands SRLs. 